💸 The Tape

Every cannabis company needs a bank. For most of the industry's history, finding one willing to say yes has been somewhere between difficult and impossible. Safe Harbor Financial has spent over a decade building the infrastructure to make that connection work — and Q1 2026 suggests the effort is finally compounding into something significant.

The Nasdaq-listed fintech platform reported Q1 revenue of approximately $2 million, up 2.2% year-over-year — a modest top line for a company with ambitious positioning. But the story at Safe Harbor has never been about a single quarter's revenue. It's about the platform being built underneath it, the regulatory transformation happening around it, and the balance sheet that just underwent what CEO Terrance Mendez called "a fundamental transformation."

The Balance Sheet Turnaround

Twelve months ago, Safe Harbor had a stockholders' deficit of negative $16.9 million. As of March 31, 2026, that figure stands at positive $6.7 million in stockholders' equity. That's a $23.6 million swing in the right direction — the kind of balance sheet rehabilitation that changes what a company can do strategically.

Cash ended the quarter at $5.9 million, with total assets of $15.7 million against $9 million in total liabilities. For a company that has historically operated under significant financial constraints, the clean balance sheet provides a foundation that didn't previously exist.

Loan Program Momentum

The most encouraging financial signal in Q1 was loan program income, which grew 55.6% year-over-year to approximately $800,000. That acceleration reflects the Second Amended PCCU Agreement, effective October 2025, which increased Safe Harbor's share of loan interest income to up to 65% — nearly double the prior 37% split. The amended partnership extends through December 2031 and is expected to generate an additional $9 million or more in incremental revenue over the term while reducing asset hosting fees by approximately 23% annually.

Account fee income declined 19% to approximately $900,000, driven by customers migrating toward money market account offerings and lower merchant service fees — a mix shift that suggests depositors are becoming more sophisticated about where they park cash, which isn't necessarily a bad thing for long-term platform stickiness.

The net loss widened to $1.8 million from $827,000 in Q1 2025, though the prior year figure benefited from a $1.1 million non-cash gain on warrant liability fair value changes that didn't recur. Adjusting for that noise, the underlying operating trajectory actually improved, with operating losses narrowing from $2 million to $1.8 million on lower total operating expenses.

Platform Expansion

Where Safe Harbor's Q1 gets genuinely interesting is in the breadth of platform capabilities being assembled.

The company expanded into cannabis insurance solutions through partnerships with Frontier Risk and AlphaRoot, offering tailored property, liability, workers' compensation, and risk management products. It added Lüt and GreenCard to its payments lineup, introducing closed-loop, ACH-debit, and end-to-end payment infrastructure covering every major cannabis payment method. And it launched a purpose-built 401(k) plan for cannabis businesses — extending the platform into employee retirement benefits.

On the lending side, Safe Harbor rolled out a full-spectrum lending platform spanning commercial real estate, working capital, equipment financing, revenue-based lending, accounts receivable financing, bridge financing, sale-leaseback transactions, business acquisition financing, and loan syndications — supported by a network of private credit funds, family offices, and institutional partners.

That's a remarkable breadth of financial services for an industry that, not long ago, struggled to open a basic checking account. Safe Harbor is positioning itself not just as a banking facilitator but as the comprehensive financial infrastructure layer for the cannabis industry — the one-stop platform where operators handle deposits, payments, insurance, lending, and retirement benefits.

The Rescheduling Catalyst

Mendez was explicit about what Schedule III rescheduling means for Safe Harbor's business model — and the logic is compelling from multiple angles.

First, the elimination of 280E on medical cannabis operations immediately improves operator cash flow. Healthier, better-capitalized cannabis businesses are better banking customers — they carry larger deposit balances, have lower churn risk, and qualify for more sophisticated financial products. Safe Harbor's existing customer base gets more valuable overnight.

Second, rescheduling is expected to draw new financial institutions into cannabis banking. As the federal risk profile diminishes, banks and credit unions that have avoided the sector will begin exploring entry — and they'll need the compliance infrastructure that Safe Harbor has spent over a decade building. The company has facilitated more than $35 billion in cannabis-related transactions across 41 states and territories and has successfully navigated 25 state and federal regulatory examinations. That track record becomes a product in itself.

"We expect the addressable market for our compliance platform to expand in two ways," Mendez said — "directly, through healthier cannabis customers, and indirectly, through new financial institution partners that need the regulatory infrastructure we have spent more than a decade building."

The Emerging Markets Signal

A quieter but potentially significant data point: average deposit balances in emerging U.S. markets grew 29% year-over-year, adding more than 100 new customer depository accounts and bringing emerging markets to 31% of Safe Harbor's total average deposit base. That geographic diversification reduces concentration risk and positions the company to capture growth in newer cannabis markets like Ohio, Minnesota, and other states where legal sales are ramping.

The Bottom Line

Safe Harbor's Q1 2026 revenue of $2 million isn't going to impress anyone scanning for top-line growth stories. But revenue is arguably the wrong lens for evaluating this company right now. The real story is the platform buildout, the balance sheet transformation, and the regulatory tailwind that could fundamentally expand the addressable market for everything Safe Harbor does.

The cannabis industry has generated over $35 billion in annual U.S. revenue while operating with a fraction of the financial services infrastructure available to any other legal industry. As that gap closes — accelerated by rescheduling, increasing institutional comfort with cannabis, and the sheer operational necessity of proper banking and lending — the company that owns the compliance backbone stands to capture an outsized share of the value.

Mendez's stated ambition is to be "the financial platform that cannabis operators reach for first and the compliance backbone that financial institutions entering this market rely on." After a decade of building through the hardest possible environment, Safe Harbor may finally have the balance sheet, the platform breadth, and the regulatory moment to make that ambition real.

📈 Dog Walkers

$GLASF ( ▲ 2.75% ) Establishes ATM

Glass House Brands is giving itself a new financial tool — and investors should pay attention to how it gets used.

The California cannabis producer filed a prospectus supplement establishing an at-the-market (ATM) equity distribution program allowing the company to sell up to US$50 million in equity shares at prevailing market prices through ATB Cormark Capital Markets. The timing, volume, and whether any shares are sold at all remain entirely at management's discretion.

The company framed the ATM as a long-term, opportunistic capital source rather than a response to immediate financial need — a distinction that matters for a company currently navigating a transitional period with negative adjusted EBITDA and compressed margins while ramping production capacity toward one million pounds of annual biomass output.

Intended uses for any proceeds include cultivation expansion, general corporate purposes, and potential acquisitions — language that's deliberately broad and gives management maximum flexibility. For a company that just completed the Greenhouse 2 buildout, is pursuing DEA registration for medical operations, and has a California retail joint venture with Vireo Growth pending, there's no shortage of places to deploy capital.

The ATM structure is increasingly common among cannabis companies because it avoids the steep discounts and dilutive terms typically associated with traditional bought deal financings. Shares are sold directly into the open market at current prices, allowing the company to raise capital incrementally when it believes pricing is favorable — rather than being forced into a large, discounted offering during a period of weakness.

That said, any ATM program carries dilution risk for existing shareholders. The key question is whether Glass House can execute the cost improvements and revenue growth it's projecting for the second half of 2026 — making any shares sold through the ATM look like well-timed capital deployment rather than survival financing.

The tool is loaded. Execution determines whether it's a weapon or a crutch.

Study Destroys “Lazy Stoner” Stereotype

The lazy stoner might be the most durable myth in cannabis — and science keeps dismantling it, one study at a time.

New federally funded research from the University of California, Riverside School of Medicine has found that whole-extract cannabis is linked to both weight loss and reduced diabetes risk in obese mice — adding to a growing body of evidence that challenges the assumption that THC-driven munchies lead to unhealthy weight gain.

The study, published in the Journal of Physiology and supported by NIH grant funding, tackled a genuine scientific paradox: if cannabinoids stimulate appetite, why do multiple studies show that cannabis users tend to have healthier body weights and lower diabetes rates than non-users?

Researchers fed mice a high-fat, high-sugar Western diet to induce obesity, then treated them with either full-spectrum cannabis extract or isolated THC for 30 days. Both treatments reduced body weight and visceral fat, but the full-spectrum extract proved significantly more effective at improving glucose regulation — normalizing glucose clearance in obese mice to levels comparable to lean mice. Isolated THC did not achieve the same result.

That distinction points to the entourage effect — the theory that cannabis compounds work better together than in isolation. Lead author Nicholas DiPatrizio said the data suggests "THC alone is not responsible for the metabolic benefits associated with cannabis use. Other compounds in the plant appear to play a critical role."

The findings align with previous research, including a 2024 study showing daily cannabis users were 32% less likely to be obese than non-users, and separate work demonstrating that a THCV-CBD combination produced statistically significant weight loss and improved cardiovascular markers.

DiPatrizio urged clinicians and policymakers to "pay attention to this space," noting the potential for developing therapeutics from non-intoxicating phytocannabinoids in the whole plant.

Source: Marijuana Moment

🗞️ The News

📺 Trade To Black

Virginia’s Moment of Truth | FDA Shakeup Raises Big Questions | TTB Presented by Flowhub

• FDA Leadership Shakeup: Michael Davis was appointed to lead the FDA's Center for Drug Evaluation and Research, bringing deep experience in psychiatric drug development and psychedelic therapeutics — a significant development as Compass Pathways advances COMP360 toward potential approval.

• Safe Harbor Earnings: Safe Harbor Financial delivered one of its cleanest quarters in years, with strong lending growth and improving balance sheet metrics as the cannabis fintech platform continues to expand.

• Virginia Decision Looms: Michael Bronstein (ATACH) joins to discuss Governor Spanberger's impending decision on Virginia's adult-use bill, with veto risk elevated after lawmakers rejected her proposed amendments.

• The Clock Is Ticking: Spanberger is expected to act later this week, and the outcome will determine whether Virginia launches legal sales or starts the legislative process over in 2027.